Clinical Trials Browser

Phase 3 × Carcinoma, Non-Small-Cell Lung × Cisplatin × Clear all

NCT04267848 2026-04-17

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06312137 2026-04-17

TroFuse-019

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03520686 2026-04-15

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT06623422 2026-04-14

INTerpath-009

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04092283 2026-04-13

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06793215 2026-04-13

Krascendo 2

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07190248 2026-04-13

KANDLELIT-007

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06875310 2026-04-07

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07128199 2026-04-07

REZILIENT4

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04205812 2026-03-31

POD1UM-304

Phase 3 Active not recruiting

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06561386 2026-03-31

RELATIVITY1093

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04129502 2026-03-30

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05555732 2026-03-25

TROPION-Lung07

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06119581 2026-03-25

SUNRAY-01

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05687266 2026-03-13

AVANZAR

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT06417814 2026-03-02

TROPION-Lung15

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03631199 2026-02-25

CANOPY-1

Phase 3 Terminated

673 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT06956001 2026-02-12

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3 Active not recruiting

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05226598 2026-02-05

MK-7684A-007

Phase 3 Completed

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06711900 2026-02-05

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03456076 2026-01-30

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

257 enrolled 14 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05502237 2026-01-30

STAR-121

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06564844 2026-01-27

TROPION-Lung12

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT05870319 2025-12-05

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06927986 2025-11-17

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06212752 2025-11-12

MK-3475A-D77

Phase 3 Active not recruiting

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Phase 3 Active not recruiting

328 enrolled 23 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04194944 2025-10-21

LIBRETTO-431

Phase 3 Active not recruiting

261 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3 Active not recruiting

461 enrolled 18 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 2 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05722015 2025-09-11

MK-3475A-D77

Phase 3 Active not recruiting

377 enrolled 17 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04380636 2025-08-17

MK-7339-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07109531 2025-08-07

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05298423 2025-08-01

KEYVIBE-006

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT07050043 2025-07-03

LEDANG

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05116462 2025-06-26

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT00981058 2025-06-18

SQUIRE

Phase 3 Completed

1,093 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT03800134 2025-06-11

AEGEAN

Phase 3 Active not recruiting

825 enrolled 3 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung